Celgene Corp. (NASDAQ: CELG) recently received a number of ratings updates from brokerages and research firms:

  • 9/18/2016 – Celgene Corp. was given a new $156.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 9/16/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Bank of America Corp.. They now have a $128.00 price target on the stock.
  • 9/13/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $137.00 price target on the stock.
  • 9/13/2016 – Celgene Corp. had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $141.00 price target on the stock.
  • 9/13/2016 – Celgene Corp. had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $162.00 price target on the stock.
  • 9/12/2016 – Celgene Corp. was given a new $156.00 price target on by analysts at Canaccord Genuity. They now have a “buy” rating on the stock.
  • 9/12/2016 – Celgene Corp. had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $120.00 price target on the stock.
  • 9/12/2016 – Celgene Corp. had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $135.00 price target on the stock.
  • 9/12/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Piper Jaffray Cos..
  • 9/12/2016 – Celgene Corp. had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $150.00 price target on the stock.
  • 9/7/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Argus. They now have a $155.00 price target on the stock.
  • 8/31/2016 – Celgene Corp. had its “equal weight” rating reaffirmed by analysts at Morgan Stanley. They now have a $120.00 price target on the stock.
  • 8/30/2016 – Celgene Corp. was upgraded by analysts at Vetr from a “buy” rating to a “strong-buy” rating. They now have a $120.45 price target on the stock.
  • 8/25/2016 – Celgene Corp. had its “outperform” rating reaffirmed by analysts at Cowen and Company. They now have a $150.00 price target on the stock.
  • 8/24/2016 – Celgene Corp. was upgraded by analysts at Vetr from a “hold” rating to a “buy” rating. They now have a $115.99 price target on the stock.
  • 8/23/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Jefferies Group.
  • 8/23/2016 – Celgene Corp. had its “outperform” rating reaffirmed by analysts at BMO Capital Markets. They now have a $141.00 price target on the stock.
  • 8/21/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at BTIG Research. They now have a $138.00 price target on the stock.
  • 8/19/2016 – Celgene Corp. had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a $136.00 price target on the stock.
  • 8/15/2016 – Celgene Corp. was given a new $145.00 price target on by analysts at Piper Jaffray Cos.. They now have a “buy” rating on the stock.
  • 8/10/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $150.00 price target on the stock.
  • 8/9/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $137.00 price target on the stock.
  • 8/8/2016 – Celgene Corp. was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Celgene’s second-quarter results were better than expected with the company beating on both top- and bottom-line estimates. Multiple myeloma (MM) drug Revlimid continued to grow on the back of market share gains and increased duration. Other key products Pomalyst/Imnovid, Abraxane and Otezla also performed well. The company’s raised and updated outlook for 2016 is also encouraging. Celgene guided earnings in the range of $5.70 to $5.75 per share, while net product sales are expected to be approximately $11 billion. Revlimid is projected to bring in sales of approximately $6.8 billion in 2016. Meanwhile, the company continues to progress with its label expansion efforts and pipeline development. It anticipates several pipeline-related events in the second half of the year and over the next few years. However, Celgene is highly dependent on Revlimid for growth. Moreover, stiff competition in target markets remain a threat.”
  • 8/5/2016 – Celgene Corp. was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $130.00 price target on the stock. According to Zacks, “Celgene’s second-quarter results were better than expected with the company beating on both top- and bottom-line estimates. Multiple myeloma (MM) drug Revlimid continued to grow on the back of market share gains and increased duration. Other key products Pomalyst/Imnovid, Abraxane and Otezla also performed well. The company’s raised and updated outlook for 2016 is also encouraging. Celgene guided earnings in the range of $5.70 to $5.75 per share, while net product sales are expected to be approximately $11 billion. Revlimid is projected to bring in sales of approximately $6.8 billion in 2016. Meanwhile, the company continues to progress with its label expansion efforts and pipeline development. It anticipates several pipeline-related events in the second half of the year and over the next few years. However, Celgene is highly dependent on Revlimid for growth. Moreover, stiff competition in target markets remain a threat.”
  • 8/3/2016 – Celgene Corp. had its “hold” rating reaffirmed by analysts at Morgan Stanley. They now have a $120.00 price target on the stock.
  • 8/3/2016 – Celgene Corp. was upgraded by analysts at BTIG Research from a “neutral” rating to a “buy” rating. They now have a $138.00 price target on the stock, up previously from $116.14.
  • 8/2/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Stifel Nicolaus. They now have a $138.00 price target on the stock.
  • 8/1/2016 – Celgene Corp. had its “market perform” rating reaffirmed by analysts at Leerink Swann. They now have a $135.00 price target on the stock, up previously from $125.00.
  • 8/1/2016 – Celgene Corp. was upgraded by analysts at Vetr from a “sell” rating to a “hold” rating. They now have a $111.26 price target on the stock.
  • 7/28/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Cowen and Company. They now have a $150.00 price target on the stock.
  • 7/28/2016 – Celgene Corp. was given a new $145.00 price target on by analysts at Piper Jaffray Cos.. They now have a “buy” rating on the stock.
  • 7/26/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at Jefferies Group. They now have a $138.00 price target on the stock.
  • 7/26/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at RBC Capital Markets.
  • 7/26/2016 – Celgene Corp. had its “buy” rating reaffirmed by analysts at BMO Capital Markets. They now have a $141.00 price target on the stock.
  • 7/26/2016 – Celgene Corp. had its “outperform” rating reaffirmed by analysts at Robert W. Baird. They now have a $162.00 price target on the stock.
  • 7/25/2016 – Celgene Corp. was downgraded by analysts at Vetr from a “hold” rating to a “sell” rating. They now have a $104.37 price target on the stock.

Shares of Celgene Corp. (NASDAQ:CELG) traded down 0.22% during trading on Wednesday, hitting $108.18. 1,378,124 shares of the stock traded hands. The firm has a market cap of $83.85 billion, a price-to-earnings ratio of 45.72 and a beta of 1.31. The stock has a 50 day moving average of $110.21 and a 200 day moving average of $105.03. Celgene Corp. has a 52-week low of $93.05 and a 52-week high of $128.39.

Celgene Corp. (NASDAQ:CELG) last posted its earnings results on Thursday, July 28th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.39 by $0.05. Celgene Corp. had a return on equity of 67.06% and a net margin of 18.95%. The company had revenue of $2.74 billion for the quarter, compared to analyst estimates of $2.70 billion. During the same quarter in the previous year, the firm earned $1.23 earnings per share. The firm’s quarterly revenue was up 20.9% compared to the same quarter last year. Analysts expect that Celgene Corp. will post $5.71 EPS for the current year.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/research-analysts-weekly-ratings-changes-for-celgene-corp-celg.html

In other news, Director James J. Loughlin sold 27,500 shares of the business’s stock in a transaction dated Tuesday, August 23rd. The stock was sold at an average price of $114.10, for a total transaction of $3,137,750.00. Following the sale, the director now owns 42,919 shares in the company, valued at $4,897,057.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Robert J. Hugin sold 100,000 shares of the business’s stock in a transaction dated Thursday, July 28th. The stock was sold at an average price of $110.00, for a total value of $11,000,000.00. Following the sale, the insider now owns 1,022,201 shares in the company, valued at approximately $112,442,110. The disclosure for this sale can be found here. 0.97% of the stock is owned by company insiders.

Celgene Corporation (Celgene) is a biopharmaceutical company. The Company together with its subsidiaries is engaged primarily in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.

5 Day Chart for NASDAQ:CELG

Receive News & Ratings for Celgene Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corp and related companies with MarketBeat.com's FREE daily email newsletter.